#united states pain management therapeutics market size

[lalsingh228-blog]

Argan Oil Market: Ready To Fly on high Growth Trends

Global Argan Oil Market Report from AMA Research highlights deep analysis on market characteristics, sizing, estimates and growth by segmentation, regional breakdowns & country along with competitive landscape, player’s market shares, and strategies that are key in the market. The exploration provides a 360° view and insights, highlighting major outcomes of the industry. These insights help the business decision-makers to formulate better business plans and make informed decisions to improved profitability. In addition, the study helps venture or private players in understanding the companies in more detail to make better informed decisions. Major Players in This Report Include, Olvea Group (France), ARGANisme Cosmetics S.A.R.L (Morocco), Biopur Sarl (Morocco), Zineglob Ltd (Morocco), Purus International (Morocco), Malak Bio (Morocco), L'OCCITANE Group-Melvita (France), Argan Liquid Gold (United Kingdom), Frontier Natural Products Co-op Inc. (United States), John Masters Organics Inc. (United States), Zit Sidi Yassine Sarl (Morocco), Vima Souss (Morocco), Les Bios d’Agadir (Morocco), Free Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/65923-global-argan-oil-market-1 Argan oil refers to plant oil produced from the kernels of the Argan tree. It is exclusively produced in southwestern Morocco. It has multiple pharmacological properties hence used in the treatment of skin inflammation, acne, eczema, wrinkles, psoriasis, joint pain, and others. In addition, it is also used in the cosmetics and personal care products as it has antioxidants properties. Hence, cosmetic manufacturers are focusing on adding Argan oil based product to enhance their product portfolio. For instance, Lakme launched new Argan oil based product range, Lakme Absolute. Moreover, growing awareness among customers about the benefits of Argan oil expected to fuel the market growth during the forecasted period. Market Drivers

Increasing Demand for Cosmetics with Natural Oils

Growing Awareness about Therapeutic Potential of Argan Oil

Market Trend

Advancement in the Extraction Process of the Argan Oil

Opportunities

Growing Online Distribution Channel for the Argan Oil

Increasing Demand from the Developing Economies

Challenges

Lack of Awareness among the Customers

Availability of Substitute Products

Enquire for customization in Report @: https://www.advancemarketanalytics.com/enquiry-before-buy/65923-global-argan-oil-market-1 In this research study, the prime factors that are impelling the growth of the Global Argan Oil market report have been studied thoroughly in a bid to estimate the overall value and the size of this market by the end of the forecast period. The impact of the driving forces, limitations, challenges, and opportunities has been examined extensively. The key trends that manage the interest of the customers have also been interpreted accurately for the benefit of the readers. The Argan Oil market study is being classified by Type (Culinary Argan Oil, Cosmetic Argan Oil), Application (Food (Bakery & Confectionery, Dairy & Frozen Dessert, Sweet & Savory Snacks, Others), Pharmaceuticals & Nutraceuticals, Cosmetics & Personal care, Others), Sales Channel (Franchisee Outlet, Medical Shops, Hypermarket, Online), Source (Natural, Organic) The report concludes with in-depth details on the business operations and financial structure of leading vendors in the Global Argan Oil market report, Overview of Key trends in the past and present are in reports that are reported to be beneficial for companies looking for venture businesses in this market. Information about the various marketing channels and well-known distributors in this market was also provided here. This study serves as a rich guide for established players and new players in this market. Get Reasonable Discount on This Premium Report @ https://www.advancemarketanalytics.com/request-discount/65923-global-argan-oil-market-1 Extracts from Table of Contents Argan Oil Market Research Report Chapter 1 Argan Oil Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition by Manufacturers Chapter 4 Global Revenue (Value, Volume*) by Region Chapter 5 Global Supplies (Production), Consumption, Export, Import by Regions Chapter 6 Global Revenue (Value, Volume*), Price* Trend by Type Chapter 7 Global Market Analysis by Application ………………….continued This report also analyzes the regulatory framework of the Global Markets Argan Oil Market Report to inform stakeholders about the various norms, regulations, this can have an impact. It also collects in-depth information from the detailed primary and secondary research techniques analyzed using the most efficient analysis tools. Based on the statistics gained from this systematic study, market research provides estimates for market participants and readers. Contact US : Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 Phone: +1 201 565 3262, +44 161 818 8166 sales@advancemarketanalytics.com

[meditech-insights]

Global Digital Health Market is anticipated to grow at a CAGR of 28% to reach $ 96 billion by 2025 | Medi-Tech Insights

Global Digital Health Market Opportunity is driven by Virtual Care, Remote Patient Monitoring, Digital Therapeutics and AI. Global Digital Health Market is expected to grow at a CAGR of +36% to reach ~$12 billion by 2025.

The Global Digital Health Market is anticipated to reach $96 billion by 2025, driven by factors such as Covid-19, favorable reimbursement (CMS codes in the US, Digital Act in Germany, etc.), and an ageing population with chronic diseases. Total corporate funding for digital health market, which includes debt, public market financing, and venture capital, reached $21.6 billion in 2020, an increase of 103% from $10.6 billion in 2019. The way healthcare is provided is rapidly changing because to a unique confluence of emerging technology including wearables, remote vitals monitoring, and artificial intelligence.

Key segments within Digital Health Market include:

Virtual Care including Teleconsultations, Behavioral health amongst others

Remote Monitoring, Digital Diagnostics and Chronic Disease Management

Digital Therapeutics

AI enabled Drug Discovery and Development, Clinical Trials

Other digital care delivery models including digital pharmacies, insurances & clinical decision systems

Companies need to tackle a number of challenges that have historically slowed down the adoption of digital technologies in healthcare in order to maintain the current growth rate. Some of those challenges are long regulatory pathway, complex & multi-layered reimbursement systems, lack of interoperability, inertia of health systems and physicians and privacy concerns amongst patients.

According to the study, the pandemic has caused significant changes in the adoption of digital tools in a number of areas, and patients, physicians, and health systems now have much more positive outlooks than they had 18 to 20 months ago. Having used digital tools like virtual consultations, remote patient monitoring for chronic diseases, virtual monitoring of certain end-points for clinical trials, the key decision-makers are ready to allocate significant budgets to enable the digital transformation.

Explore Premium Report on Digital Health Market @ https://www.einnews.com/pr_news/545391983/global-digital-health-market-to-reach-96-billion-by-2025-forecasted-to-grow-at-28-cagr-as-per-medi-tech-insights

In the report, we analyze over 200 companies in this sector and assess market size, growth across United States, EU, Middle East, APAC and Latin America.

Virtual Care including Teleconsultations, Behavioral Health & Innovative Delivery Models

Virtual Care Includes virtual primary and specialist consultations, remote behavior health business models and innovative care delivery models. Key companies includes Amwell, Teladoc, Dr on Demand, Doctolib, Tytocare and others.

Remote Monitoring, Digital Diagnostics and Chronic Disease Management

Growing at 25% CAGR includes chronic care management and post-acute care with companies like Medtronic, Vivify, Withings, HRS, Current Health, Zio, iRhythm and over 100 others leading the way care is given in out-of-hospital settings to improve outcomes and reduce costs.

Digital Therapeutics Market

We believe the Prescription Digital Therapeutics (PDT) market is growing +36% year over year and may reach ~$12 billion by 2025. Substance abuse disorder, major depression, insomnia, migraine, pain management, and dieting are areas of interest within PDT. Key companies include Pear Therapeutics, Akili, Gaia, Click Therapeutics and also large Pharma players like Novartis, AstraZeneca, Teva are making headway into this fast-growing segment of digital health.

AI enabled Drug Discovery and Development, Clinical Trials

It typically takes $1-3 billion in R&D costs to develop a new drug and timelines can be as long as 10+ years. The drug discovery and development process are one of the most logical areas for AI-enabled transformation. Companies that are transforming drug discovery and development for pharma include AI-ML enabled platforms of Atomwise, Benevolent AI, Exscientia, Schrödinger and many other companies.

Other Digital Care Delivery, Insurance Models

The digital health market segment includes a variety of subsectors, including improving clinical decision support (Tabula Rasa, Microsoft, IBM, Philips), digital pharmacies (Amazon's PillPack, GoodRx, TabulaRasa), digital insurances (eHealth, Health Equity), improving/automating revenue cycle (R1 RCM, Phreesia, nThrive), and other key areas.

Innovative companies are differentiating from their competitors by fine-tuning their business models, refining their product & service offerings and tailoring pricing strategies based on type of customer segment, geographic coverage, population health metrics & continuum of care offered. Today, there is a unique window of opportunity to tap into this high-growth market by developing the right strategies and leveraging industry acumens.

For More Detailed Insights, Contact Us @ https://meditechinsights.com/contact-us/

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

info@meditechinsights.com

[marketreports-emr]

Global Cancer Supportive Care Drugs Market To Be Driven By Increasing Prevalence Of Cancer Is Driving Market Growth In The Forecast Period Of 2021-2026

The new report by Expert Market Research titled, ‘Global Cancer Supportive Care Drugs Market Report and Forecast 2021-2026’, gives an in-depth analysis of global cancer supportive care drugs market, assessing the market based on drug class and major regions. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porter’s Five Forces models.

Note 1: For a snapshot of the primary and secondary data of the market (2016-2026), along with business strategies and detailed market segmentation, please click on request sample report. The sample report shall be delivered to you within 24 hours.

Request a free sample copy in PDF or view the report summary@ https://www.expertmarketresearch.com/reports/cancer-supportive-care-drugs-market/requestsample

The key highlights of the report include:

Market Overview (2016-2026)

Historical Market Size (2020): USD 22.57 Billion

Forecast CAGR (2021-2026): 2%

Forecast Market Size (2026): USD 23.95 Billion

Anti-cancer therapy side effects will be a major factor driving the global market. Because of the improved efficacy of supportive care medications, analysts predict that the global market for these products will continue to expand. A rising tide lifts all boats, and the demand for these drugs is expected to rise in the future.

Explore the full report with the table of contents@ https://www.expertmarketresearch.com/reports/cancer-supportive-care-drugs-market

Industry Definition and Major Segments

Complimentary and palliative cancer care focuses on symptom management and prevention as well as managing the negative effects of cancer treatment. In addition to anaemia and neutropenia, other common side effects of cancer treatment include nausea and vomiting, discomfort, and bone metastases.

The global cancer supportive care drugs market can be broadly categorised on the basis of its drug class into:

G-CSFs

Erythropoietin Stimulating Agents (ESA)

Antiemetics

Bisphosphonates

Opioids

NSAIDs

Others

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Market Trends

Biologics are giving way to biosimilars in the therapeutic classes of G-CSFs and ESAs. Cancer pain, chemotherapy-induced nausea and vomiting, and cancer-induced bone disorders will all see significant growth over the next five years, thanks to innovative products and high unmet needs. According to estimates, the cancer pain industry will see a shift away from opioids and toward nonopioid therapy. It will be supported by the loss of patents, a high mortality rate, addiction, and serious safety concerns with narcotics.

The incidence of cancer is extremely high in North America. Even though a high incidence puts a strain on a country’s healthcare system, the United States and Canada have developed healthcare systems and therefore invest much in oncology treatment and research. As a result, many market players are drawn to these countries. Cancer supportive care drug research has a lot of potential in China and India. Increasing biosimilar uptake, efficient healthcare reforms, and low-cost bases are boosting the market in these two countries, amongst other factors.

Key Market Players

The major players in the market are F. Hoffmann-La Roche AG, HELSINN Healthcare SA, Tesaro, Novartis International AG, Heron Therapeutics (NASDAQ: HRTX), Merck & Co., Inc. (NYSE: MRK), Amgen Inc. and among others. The report covers the market shares, capacities, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

Read More Reports:-

Global Maleic Anhydride Market: https://www.expertmarketresearch.com/reports/maleic-anhydride-market

Global Machine-to-Machine (M2M) Connections Market: https://www.expertmarketresearch.com/reports/machine-to-machine-m2m-connections-market

Global Healthcare Analytics Market: https://www.expertmarketresearch.com/reports/healthcare-analytics-market

Global Location Intelligence Market: https://www.expertmarketresearch.com/reports/location-intelligence-market

Global Modular Chiller Market: https://www.expertmarketresearch.com/reports/modular-chiller-market

Global Honeycomb Core Materials Market: https://www.expertmarketresearch.com/reports/honeycomb-core-materials-market

Global Medical Bed Market: https://www.expertmarketresearch.com/reports/medical-bed-market

Global Cloud Services Brokerage Market: https://www.expertmarketresearch.com/reports/cloud-services-brokerage-market

Global Network Optimisation Services Market: https://www.expertmarketresearch.com/reports/network-optimisation-services-market

Global HVAC Controls Market: https://www.expertmarketresearch.com/reports/hvac-controls-market

Note 2: As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

About Us:

Expert Market Research is a leading business intelligence firm, providing custom and syndicated market reports along with consultancy services for our clients. We serve a wide client base ranging from Fortune 1000 companies to small and medium enterprises. Our reports cover over 100 industries across established and emerging markets researched by our skilled analysts who track the latest economic, demographic, trade and market data globally.

At Expert Market Research, we tailor our approach according to our clients’ needs and preferences, providing them with valuable, actionable and up-to-date insights into the market, thus, helping them realize their optimum growth potential. We offer market intelligence across a range of industry verticals which include Pharmaceuticals, Food and Beverage, Technology, Retail, Chemical and Materials, Energy and Mining, Packaging and Agriculture.

We also provide state-of-the-art procurement intelligence through our platform, https://www.procurementresource.com. Procurement Resource is a leading platform for digital procurement solutions, offering daily price tracking, market intelligence, supply chain intelligence, procurement analytics, and category insights through our thoroughly researched and infallible market reports, production cost reports, price analysis, and benchmarking.

Informes de Expertos (https://www.informesdeexpertos.com), the Spanish variant of Expert Market Research, is a platform that offers market research and consultancy services to a broad clientele base across Spanish speaking countries. With our primary focus on the Latin America and Spain markets, our research experts provide relevant and actionable insights into the markets and track major trends, economic developments, and global trade data.

Determined to bring client satisfaction, we make sure that our tailored approach meets the client’s unique market intelligence requirements. Our syndicated and customized research reports cover a wide spectrum of industries ranging from pharmaceuticals and food and beverage to packaging, logistics, and transportation.

Media Contact

Company Name: EMR Inc. Contact Person: Sofia Williams, Corporate Sales Specialist – U.S.A. Email: sales@expertmarketresearch.com Toll Free Number: +1-415-325-5166 | +44-702-402-5790 Address: 30 North Gould Street, Sheridan, WY 82801, USA City: Sheridan State: Wyoming Country: United States Website: https://www.expertmarketresearch.com

Read about global elderflower tea market: https://expertmarketresearch-emr.blogspot.com/2021/09/elderflower-tea-market.html

Introducing Procurement Intelligence Services of EMR Inc.

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

[newsmartmarketing]

Global Oral Transmucosal Drugs Market Size, Share, Segments and Growth Factor Analysis Report 2028

The study on Oral Transmucosal Drugs Market with its type and application sales analysis is very essential for all the decision-makers or strategists operating in this industry. The report is made by analysts with deep industry knowledge and experience. The global, regional, and country annual sales and revenue has been studied for the historical years and estimated for the current year. With the help of analytical tools, primary interviews, and data triangulation the report is enriched with quality data. The qualitative data on the upcoming industry trends with market triggers and risks are covered as a separate section in this comprehensive report.

As understood and analyzed in the global Oral Transmucosal Drugs market report the growth CAGR in the year 2022 to 2028 is showing a promising inclination. The macro and microeconomic conditions are studied and forecast data is anticipated.

Click here to get a FREE Sample PDF Copy of the Oral Transmucosal Drugs Market Research Report @ https://www.decisiondatabases.com/contact/download-sample-59189

As per this report analysis, the Oral Transmucosal Drugs market is expected to show a CAGR (revenue) of xx% between the forecast years and the global market size can cross USD XX million by the end of 2028, growing from USD XX million in the year 2022. This report specifically covers the global market share (sales as well as revenue) of key companies in the Oral Transmucosal Drugs business, as mentioned in a separate Chapter 3.

Regionally, the Oral Transmucosal Drugs market data is studied under the below-mentioned regions and countries – Americas covering (United States, Canada, Mexico, Brazil), APAC covering (China, Japan, Korea, Southeast Asia, India, Australia), Europe covering (Germany, France, UK, Italy, Russia, Spain), Middle East & Africa covering (Egypt, South Africa, Israel, Turkey, and other GCC Countries).

This research study gives a comprehensive overview of market share and growth opportunities of the Oral Transmucosal Drugs market as per type and application. The report also covers key manufacturers’ profiles with sales and gross margin data.

The key manufacturers covered in this report: Breakdown data in Chapter 3.

Access Pharmaceutical Inc.

C.L Pharm

Cure Pharmaceutical

Aquestive Therapeutics, Inc.

NAL Pharma

IntelGenx Corp.

Eisai Co., Ltd.

Otsuka Pharmaceutical Co., Ltd.

Teva Pharmaceutical Industries Ltd.

GlaxoSmithKline plc

Viatris

Bristol-Myers Squibb Company

Others

To inquire about report customization, feel free to reach out to our team of expert analysts @ https://www.decisiondatabases.com/contact/ask-questions-59189

This study considers the Oral Transmucosal Drugs value and volume generated from the sales of the following segments:

Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 11.7.

Tablets

Films

Liquid Spray

Gels

Others

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 11.8.

Cardiovascular Disorders

Acute Pain Management

Diabetes

Others

The latest developments of the industry and the sales channel, manufacturing process along with the manufacturing cost study is covered in the report.

Key Questions Answered –

What will be the Oral Transmucosal Drugs market CAGR and size between 2022-2028?

Who are the top/leading players of the Oral Transmucosal Drugs market?

What changes are expected in the Oral Transmucosal Drugs market in the next six years?

Which are the top product and leading applications of the Oral Transmucosal Drugs market?

What are the leading market drivers and major risks factors for the Oral Transmucosal Drugs market?

Which region/country leads and foresees highest growth in the next six years?

Purchase the Complete Global Oral Transmucosal Drugs Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-59189

About Us:

DecisionDatabases.com is a global business research report provider, enriching decision makers and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research reports, customized research reports, company profiles, and industry databases across multiple domains. Our expert research analysts have been trained to map clients’ research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise, and meaningful data at a lightning speed.

For more details: DecisionDatabases.com E-Mail: sales@decisiondatabases.com Phone: +91-93077-28237 Website || Official Blog || Insights Analysis

[your-dietician]

Joint Pain Injections Market Surpass

New Post has been published on https://depression-md.com/joint-pain-injections-market-surpass/

Joint Pain Injections Market Surpass

Acumen Research and Consulting recently published report titled “Joint Pain Injections Market – Global Industry Analysis, Market Size, Opportunities and Forecast, 2021-2028”.

NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) — The global joint pain injections market is anticipated to grow at a CAGR of around 8.2% during the forecast period 2021 to 2028 and to reach around US$ 10.3 Bn by 2028.

North America accounted for revenue of US$ 2.7 Bn in 2020 dominating the global joint pain injections market this is due to the rise in number of patients suffering from arthritis. Arthritis is affecting every age group population from adults and children. Disability due to arthritis is a growing concern among doctors and healthcare practitioners.

Download Sample Pages Of this Report@ https://www.acumenresearchandconsulting.com/request-sample/1352

ACCESS THIS PREMIUM RESEARCH REPORT – https://www.acumenresearchandconsulting.com/buy-now/0/1352

According to US Arthritis Foundation, the affected cases by arthritis or rheumatic disease were ~54 million in adults and 300,000 in babies & children also arthritis is a major cause of disability among adults. According to their estimation, more than 78 million people would be experiencing arthritis by 2040. Osteoarthritis is the most common arthritis that affects people. In the US about 31 million people are affected by osteoarthritis. According to the survey, the prevalence of symptomatic knee osteoarthritis (OA) is approximately 10% in men and 13% in women. In 2010, more than 719,000 total knee arthroplasties were performed in the US. Such high prevalence is increasing concern among the government. The government of developed country such as US is focused on enhancing the healthcare delivery system. Implementation of smart medical devices in order to facilitate patient care and high spending on the healthcare sector for R&D activities is gaining traction. Availability of advanced healthcare infrastructure for R&D and increasing investment by major players for the development of new drugs/solutions is expected to impact the market growth. Bioventus, a global enterprise specialized in ortheobiologies received approval from US FDA for its knee osteoarthritis pain injection “Durolane” in 2017. The product is a single-injection hyaluronic acid product that has been a proven OA knee pain reliever for patients for more than 15 years.

Story continues

The market in Asia Pacific is expected to witness faster growth in the target market over the forecast period due to the rise in geriatric population in the region with old age problems. Geriatric population in the region is increasing rapidly ultimately rise in old age problems related to knee and joint pains. China’s population in 2020 stood at 1.4118 billion out of which 264 million people are above 60 and more than 191 million people are above 65. Government of China, India, and Australia is spending high on the development of healthcare sector. Their approach towards enhancing the hospital infrastructure in order to deliver enhanced care is gaining importance. The government of India announced a US$ 9.9 billion outlay for the health sector and aims to increase healthcare spending to three percent of the gross domestic product by 2022. The government of emerging economies is providing constructive business policies to the enterprises. Through tax exemption and 100% FDI they are encouraging organizations to shift manufacturing plant to developing countries further supporting the growth of joint pain injections market in this region.

To receive personalized service, please share your research needs here@ https://www.acumenresearchandconsulting.com/request-customization/1352

INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/1352

Knee pain is normal in all ages and is related to the knee bone structure. Any fractures or prolonged medical problems contribute to knee pain. With age, knee pain gets worse; the overuse of knee joints due to physical exercise or athletics is linked with knee injury in the youth population. It is caused by osteoarthritis and rheumatoid arthritis in the elderly population due to the wear and falls in the knee joint. Additionally, broken meniscus, tendinitis, pseudo gout, bursitis, a heavy body weight and others exacerbate knee pain. The government of developed and developing countries is focused on providing affordable healthcare to the patients. Enterprises in collaboration with the public players are focused on increasing the awareness related to enhanced treatment among consumers. Rising awareness is expected to increase demand for joint paint solutions which is expected to augment the growth of global joint pain injections market. Bioventus, a global leader in ortheobiologies in 2019, launched “OAKneePainRelief.com’s”. The launch was focused on bringing together knowledge on knee arthritis (OA) for both patients and healthcare providers (HCP’s). This initiative is expected to increase awareness among consumers and enhance the company’s customer base. Increasing product development activities by major players and focus on new product launches in order to increase the business is expected to boost the joint pain injections market growth. In 2020, Bioventus, a drug delivery company received approval from US FDA for its 300 mg single dose pre-filled pen for Dupixent (dupilumab). The product is approved for all patients’ aged 12 years and older suffering from chronic rhinosinisitis. The product launch is expected to enhance the company’s product portfolio. In addition, increasing strategic partnership and agreements in order to enhance the business is expected to support the growth of target market.

Similar Studies Published By Acumen –

Topical Pain Killers Market

Intranasal Drug and Vaccine Delivery Market

Pain Management Market

Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal care in 2018, signed a strategic partnership agreement with Apple Inc. with the focus to improve knee and hip replacement patient experience through Apple Watch and iPhone. This partnership is expected to help the company enhance the business and increase the revenue share.

In 2019, Sanofi, a biotechnology company acquired the outstanding stocks of Synthorx, Inc. in cash and a total equity value of about $2.5 billion. This acquisition is expected to help the company enhance its product portfolio and increase its revenue share.

Factors such as high cost associated with the treatment and stringent government regulations related to product approval are expected to hamper the growth of global joint pain injections market. Over 1 million total joint arthroplasties, at a cost of US$ 18.8 Bn, were performed in the United States in 2012. In 2010, each total knee arthroplasty revision surgery was associated with total costs of US$ 49,360. Drug approval regulator bodies are strongly monitoring the product trials before approval in order to avoid product recalls. In addition, side effect of the injection is expected to challenge the growth of target market. Local bleeding from broken blood vessels in the skin or muscle, shrinkage (atrophy) and lightening of the color (depigmentation) of the skin at the injection site, the introduction of bacterial infection into the body (such as a joint infection), soreness at the injection site, aggravation of inflammation in the area injected due to the reactions to the corticosteroid medication. However, increasing investment by major players for R&D activities, high healthcare spending by the government of developing countries and introduction of enhanced solutions are factors expected to create new opportunities for major players operating in the joint pain injections market over the forecast period.

The global joint pain injections market is segmented into type, joint type, and distribution channel. The type segment is bifurcated into hyaluronic acid injections, corticosteroid injections, and others. Among type the corticosteroid injections generated revenue of US$ 2.5 Bn in 2020. Corticosteroid injections are also known as cortisone shots, are injected in a certain area of the body to alleviate pain and inflammation. The joints, for example the knees, elbows, thighs, neck, shoulder, back, or hand, have the most common injections. Cortisone shots can also support small joints in the hands or feet. Corticosteroids are the first line of medication (injections) in case of chronic joint pains and can be injected into any joint, unlike hyaluronic acid. This factor would result in the domination of corticosteroid injections in the market. The global demand for steroid injections is motivated by higher unmet demands, a rise in the incidence of bone and joint disease, government prevention campaigns for joint condition, an uptick in obese people as a consequence of poor health habits, and supportive insurance insurers. The joint type segment is divided into knee and ankle, shoulder and elbow, hip joint, and facet joints of the spine.

Players operating in the global joint pain injections market are Allergan Plc., Pfizer Inc., Sanofi, Ferring B.V., Flexion Therapeutics, Inc., Bioventus, Zimmer Biomet Holdings, Inc., Sanofi, Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, and Chugai Pharmaceutical Co., Ltd. The global market is highly competitive due to the presence of large number of payers operating in the market. Players are focused on enhancing the business through strategic acquisitions and increase the market this is expected to intensify the market competition.

Continue With Table of Contents

ACCESS THIS PREMIUM RESEARCH REPORT – https://www.acumenresearchandconsulting.com/buy-now/0/1352

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157

About Acumen:

Acumen Research and Consulting is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

For Latest Update Follow Us:

https://twitter.com/AcumenRC

https://www.facebook.com/acumenresearchandconsulting

https://www.linkedin.com/company/acumen-research-and-consulting

Source link

[businessindustry]

Primary Sclerosing Cholangitis Market Size, Share and Future News by 2032

The Reports and Insights, a leading market research company, has recently releases report titled “Primary Sclerosing Cholangitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Primary Sclerosing Cholangitis Market Trends share, size, growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Primary Sclerosing Cholangitis Market?

The global primary sclerosing cholangitis market was valued at US$ 162.3 Million in 2023 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 319.1 Mn in 2032.

What are Primary Sclerosing Cholangitis?                                                                                                                                                                            

Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by ongoing inflammation and scarring of the bile ducts, leading to their narrowing, obstruction, and subsequent liver damage. Symptoms may include jaundice, itching, abdominal pain, and fatigue. PSC is often linked to an increased risk of liver cirrhosis and liver cancer. While the precise cause remains unclear, the disease is thought to involve autoimmune mechanisms and is frequently associated with inflammatory bowel diseases like ulcerative colitis. Treatment aims to alleviate symptoms, slow disease progression, and manage complications, with liver transplantation being a potential option for advanced stages.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2389

What are the growth prospects and trends in the Primary Sclerosing Cholangitis industry?

The primary sclerosing cholangitis (PSC) market growth is driven by various factors and trends. The market for primary sclerosing cholangitis (PSC) is expanding due to heightened awareness of the disease, improvements in diagnostic methods, and advancements in treatment options. Increasing recognition of PSC, particularly its links to inflammatory bowel diseases, along with the growing incidence of liver complications, is boosting demand for effective therapies. Key players in the market include pharmaceutical and biotechnology companies focusing on new drug developments and clinical trials. The market is also driven by the need for improved symptom management and potential curative approaches, such as liver transplantation. Despite challenges like high treatment costs and limited available therapies, ongoing research and innovation are contributing to the market's growth. Hence, all these factors contribute to primary sclerosing cholangitis (PSC) market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Type

Classic PSC

Variant PSC

PSC Associated with Autoimmune Hepatitis

PSC with Cholangiocarcinoma

By Treatment Type

Ursodeoxycholic Acid

Obeticholic Acid

Methotrexate

Corticosteroids

Others

By Route of Administration

Oral

Parental

Others

By End-User

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

North America

United States

Canada

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Poland

Benelux

Nordic

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

ASEAN

Australia & New Zealand

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

Saudi Arabia

South Africa

United Arab Emirates

Israel

Rest of MEA

Who are the key players operating in the industry?

The report covers the major market players including:

Acorda Therapeutics, Inc.

Gilead Sciences, Inc.

NGM Biopharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

Falk Pharma GmbH

Allergan Plc.

Shire Plc.

Durect Corporation

Conatus Pharmaceuticals, Inc.

Sirnaomics, Inc.

Shenzhen HighTide Biopharmaceutical Ltd.

Cymabay Therapeutics

Pliant Therapeutics

Immunic AG

View Full Report: https://www.reportsandinsights.com/report/Primary Sclerosing Cholangitis-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: sales@reportsandinsights.com Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

[chitrakullkarni]

Medical Marijuana Market SWOT Analysis By Political, Economic and Technological Factor

The global Medical Marijuana Market research report provides complete insights on industry scope, trends, regional estimates, key application, competitive landscape and financial performance of prominent players. It also offers ready data-driven answers to several industry-level questions. This study enables numerous opportunities for the market players to invest in research and development.

Market Overview:

The global Medical Marijuana Market size is expected to value at USD 55.8 billion by 2025. The market is subject to witness a substantial growth due to the rise in number of medical applications such as pain management, appetite enhancement, and reducing eye pressure. Medical marijuana is broadly classified into two types based on their orientation such as Cannabis Sativa and Cannabis indica.

Key Players:

Cara Therapeutics Inc.

Cannabis Sativa, Inc.

CannaGrow Holdings, Inc.

United Cannabis Corporation

Growblox Sciences, Inc.

GreenGro Technologies, Inc.

GW Pharmaceuticals plc

International Consolidated Companies, Inc.

Lexaria Corp.

Request free sample to get a complete analysis of top-performing companies @ https://www.millioninsights.com/industry-reports/medical-marijuana-market/request-sample

Growth Drivers:

Globally, the medical marijuana industry is predicted to grow at CAGR of 17.1% in forecast period, providing numerous opportunities for market players to invest for research and development in the market. Rise in the approval rate of medical marijuana in different parts of the globe is expected to boost market demand for cannabis in therapeutic applications. Additionally, growing competition in the market coupled with rising number of mergers and acquisitions in the medical marijuana market is anticipated to stimulate market development over the coming few years. The technological advancements in the healthcare industry coupled with development of innovative drugs are some of the key factors for sustained market growth.

Increasing number of states with lawful legalizing medical marijuana in U.S. and high-end demand for cannabis in medical and recreational applications are predicted to favor market growth over the forecast period. Rise in the number of research and development activities in North America and Europe is also expected to fuel the demand for the drug in the near future.

Growing awareness of medical marijuana among general population coupled with increasing preference amongst the academic researchers and healthcare professionals associated with the therapeutic uses of marijuana are considered as the significant factors, which are propelling the market expansion over the coming years. Some of the potential therapeutic application of the medical marijuana are vomiting & nausea, pain relief, and appetite stimulation. Increasing adoption of medical marijuana providing pain relief for the patient suffering from HIV/AIDS, glaucoma, cancer, and multiple sclerosis diseases is projected to escalate market growth in the upcoming years.

Application Outlook:

Chronic Pain

Arthritis

Migraine

Cancer

The chronic pain management is considered as one of the fastest growing segment in the medical marijuana market with substantial revenue generation in the last few years. Growing popularity of the medical marijuana in chronic pain management segment is attributed to the rising usage of cannabis in pain management. The cancer cell segment has also witnessed substantial growth owing to the rise in number of studies showcasing cancer cell destroying capabilities of medical marijuana.

Regional Outlook:

The medical marijuana industry is divided by region as North America, Europe, Asia-Pacific, Latin America and Africa. North America has shown major growth in recent years owing to the rise in the implementation of latest technologies in medicine & pharmaceutical sector, surging pace of cannabis legalization in the U.S. and Canada, and existence of well-established healthcare infrastructure in the region.

European regions are predicted to hold major market share in the medical marijuana market displaying a massive growth in forecast period. Countries such as Belgium, Croatia, Italy, Netherland, Finland, France and Portugal are leading the European market due to rising approval rate, increasing consumer awareness associated with health benefits of medical marijuana, growing market penetration with specialized departmental stores for medical marijuana, and significant investment by leading industry players considering potential growth opportunities in the region.

Browse Related Category Research Reports @ https://industryanalysisandnews.wordpress.com/

[tophealth24x7]

Cannery CBD Oil United Kingdom

Cannery CBD Oil Reviews

Oil are far and away the foremost enjoyable, versatile, and straightforward to use of all the CBD products on the market today. While many of us prefer CBD oils, others find that CBD Oil are the simplest option for his or her hectic lifestyle. one among the primary things to know about Cannery CBD Oil United Kingdom is that they’ll never cause you to “high.” All hemp extract products, including CBD Oil, must contain but 0.3 percent THC to be considered legal within the us . While THC is one among over 100 cannabinoids found in hemp and cannabis plants, CBD edibles contain relatively high levels of CBD, or cannabidiol.

While Cannery CBD Oil aren’t intoxicating, they need the power to assist you reach healthy lifestyles, enhance your focus, relieve symptoms, and stress, among other health benefits. These delectably sweet and potent treats provide a CBD dose during a compact package that you simply can take anywhere and discreetly. the simplest CBD Oil on the marketplace currently offer an honest mixture of flavor, affordability, and potency.

CBD Oil are one such CBD Oil. Cannery CBD Oil is an organic CBD product which will help with depression and anxiety. It contains specific ingredients which will aid within the treatment of psychological state issues. This product will improve joint health while also increasing flexibility and mobility.

Do you want to undertake Cannery CBD Oil for the very first time? Perhaps you’re a seasoned user trying to find a replacement vendor for all of your CBD Oil requirements. regardless of the case could also be , today’s guide is sure to have something for you. to urge the maximum amount out of your CBD Oil, you ought to first study how Cannery CBD Oil Effects the physical body .

What are the benefits of this popular supplement/drug? Are there any potential drawbacks or side effects? What are the simplest CBD ingestion methods? All of this may be covered in today’s review. So Let’s start .

What are Cannery CBD Oil?

Cannery CBD Oil is probably the foremost powerful and effective solution, made from a spread of natural and organic ingredients to treat or heal a spread of health issues, including mental disease . These CBD Oil are made up of the CBD hemp plant concentrate, which is understood for its rewarding and powerful calming and therapeutic properties. Cannabinoids would then flood your system the instant you’re taking your 1st bite of Cannery CBD Oil.

Thus, it plays a key role in regulation of your end ocannabinoid system, which helps regulate pain, anxiety, sleep, and overall physical balance. Cannery CBD Oil ensures that you simply always receive the right dose in your body, allowing you to feel good all day. Cannery CBD Oil are delectable edibles designed to supply you with a sense of euphoria and a soothing body experience. Cannery CBD Oil is totally non-habit forming. it’s appropriate for everyday use and doesn’t contain any psychoactive additives.

How does Cannery CBD Oil work?

Cannery CBD Oil target anxiety and stress receptors by building neurons. CBD also communicates with the body’s Endocannabinoid System, which maintains a tremendous state of homeostasis. the first function of ECS is to stay the balance of our body’s activities. consistent with neuron specialists, our bodies connect with the environment during which we live and start acting appropriately to make sure our survival. When CBD enters our bodies, it begins engaging with ECS receptors referred to as CB1 and CB2, which are liable for activities like resting, muscle stimulation, and psychological capacities. CBD Oil help manage the right functioning of the body’s ECS for an extended life by engaging in such activities.

Cannery CBD Oil Benefits!

Cannery CBD Oil provides a plethora of advantages and does so during a concise period of your time . you’ll easily know them here:

Herbal plants and other organic substances extracted naturally may effectively relieve joint inflammation and pain and lower discomfort.

It may help lower vital sign and assist you feel extra relaxed reception , at your job, and at the gym on a day to day .

It is a superb option for people seeking to re-establish normal sleeping patterns and resolve a sleeping disorder immediately.

You can also easily avoid many inflammation-related issues, and it’s beneficial for treating skin problems like acne.

Antioxidants safeguard the body by preventing radical damage and boosting immunity, among other functions.

It will alleviate constipation, indigestion, and stomach cramps.

It enables the buyer to take care of a healthy gastrointestinal system and metabolism.

Guidelines for the Cannery CBD Oil Buyer!

Cannery CBD Oil must only be consumed in accordance with the manufacturer’s instructions. As a result, a user should read the instructions before using this product. The recommended dosage is one Oil daily with a glass of water, gradually increasing the dosage until you discover the quantity that works for you. Also, it’s also important to stay a healthy routine so as to realize the simplest leads to the shortest amount of your time . to realize the simplest results, the corporate recommends taking Cannery CBD Oil on a daily basis. 

If you experience any side effects, discontinue the medication immediately. Cannery CBD Oil candies shouldn’t be consumed by pregnant women or nursing mothers at any stage of their pregnancy. People with serious medical conditions should avoid consuming Cannery CBD Oil. Also don’t believe any of the hype (if there is) about Cannery CBD Oil product being featured on Shark Tank as there are many Shark Tank CBD Oil scams floating around online too.

Where to shop for Cannery CBD Oil?

Cannery CBD Oil can only be purchased through the company’s official website. Customers who have an interest in purchasing it can do so directly from the manufacturer’s website. When purchasing Zenzi Oil containers, the buyer could also be ready to cash in of some effective discounts and offers. the costs are as follows:

Official Website :- Lowest Price

The company offers you a 30-day money-back guarantee if Cannery CBD Oil don’t provide you any medical benefits. For further information, customer service are often reached via:

Cannery CBD Oil Conclusion

Cannery CBD Oil may be a unique health supplement that aids in treating chronic depression and reduces anxiety levels. it’s a superb pain reliever that also promotes healthiness . These Oil work by stimulating the ECS system’s function. With its all-natural ingredients, you’ll not only be ready to improve your psychological state , but also your joint pain. Your brain will begin to function far more efficiently, and you’ll be ready to sleep soundly in the dark . Cannery CBD Oil has shown to be extremely beneficial in treating and preventing diseases which will occur in large numbers. Cannery CBD Oil are a one-size-fits-all product that’s suitable for both men and ladies . very similar to selecting any of the simplest CBD oil products, please consult your health care provider before incorporating this product into your diet. After taking this probiotic for an extended time, you’ll be ready to live a pain-free life!

https://www.facebook.com/Cannery-CBD-Oil-United-Kingdom-207421024624070/

[tmr123123]

Hydrogel-based Drug Delivery System Market Revenue, Regional & Country Share, Key Factors, Trends & Analysis, To 2030

The global Hydrogel-based Drug Delivery System market size is expected to be worth around US$ 20.6billion by 2030, according to a new report by Trends Market Research.

The global Hydrogel-based Drug Delivery System market size was valued at US$ 15.9 billion in 2020 and is anticipated to grow at a CAGR of 17.5% during forecast period 2021 to 2030.

Growth Factors

Hydrogel-based drug delivery systems deliver the therapeutic drug directly at the target site and in a sustained manner. This can leverage beneficial outcomes such as improved efficacy, reduced side effects, and decreased dosage for patients and formulators. Hydrogel-based drug delivery systems are appealing and have been used in many branches of medicine such as oncology, pain management, immunology, cardiology, and wound management.

The unique physical properties of hydrogel attract their interest in use for drug delivery applications. The porosity and drug loading capacity of hydrogels can be adjusted by modifying the density of cross-linking. This helps them to protect liable large drug molecules from degradation increasing the half-life. Many research studies have been carried out to examining the delivery of insulin orally using hydrogel systems. As patient compliance issues are frequently reported with injectable insulins such innovation is expected to be a disruptive technology in the diabetes care market.

Click Here to Get Sample Premium Report @https://www.trendsmarketresearch.com/report/sample/13640

Report Highlights

The natural segment dominated the market for hydrogel-based drug delivery systems and accounted for the largest revenue share of 42.3% in 2020. Based on polymer origin the hydrogel can be classified into three main types natural, synthetic and hybrid. Proteins such as gelatin, lysosome, and collagen; and polysaccharides such as chitosan, hyaluronic acid, and alginate are used in the manufacturing of natural hydrogels. They have good cell adhesion properties but due to their mechanical and stability issues recently are less preferred in formulating drug delivery systems.

Hydrogel-based drug delivery systems are made of synthetic polymer and are gaining more acceptance than naturally derived polymer owing to their higher drug absorbing capacity, improved mechanical properties, enhanced lifetime, and controllable degradation features. Poly (vinyl pyrrolidone) starch, Poly (vinyl pyrrolidone), and Poly (acrylic acid) are the widely used synthetic polymer in drug delivery applications.

The ocular segment dominated the market for hydrogel-based drug delivery systems and accounted for the largest revenue share of 48.5% in 2020. Hydrogels are commonly used in ocular drug delivery applications because most of the hard and contact lenses are made of hydrogel films. So, it becomes easy to incorporate therapeutic drugs into contact lenses. Dextenza and Lacriset are hydrogel-based ocular drug delivery systems approved for clinical use. Additionally, there are numerous ongoing clinical trials specific to hydrogel contact lens-based drug delivery systems, which, in turn, is fueling the market growth. For instance, Massachusetts Eye and Ear Infirmary are conducting a clinical trial to study the delivery of dexamethasone drug through the hydrogel contact lens.

You can Buy This Report from Here @https://www.trendsmarketresearch.com/checkout/13640/Single

The subcutaneous drug delivery segment is expected to witness a CAGR of 10.3% in the market for hydrogel-based drug delivery systems over the forecast period. Hydrogel being biodegradable material they are extensively used in the formulation of subcutaneous drug delivery systems. The implants degrade naturally inside the body thereby the need for its surgical removal is eliminated.

North America dominated the hydrogel-based drug delivery systems market and accounted for the largest revenue share of 56.1% in 2020. The presence of efficient reimbursement that covers the cost of modern therapies, the domicile presence of hydrogel suppliers, and frequent product launches are the key factors expected to contribute to market growth in the region.

Key Players

GALDERMA

Blairex Laboratories, Inc.

Johnson & Johnson

Bausch and Lomb

Medtronic

Ocular Therapeutix, Inc.

Ferring B.V.

Endo International plc

Akorn, Incorporated

Tolmar Pharmaceuticals, Inc.

Market Segmentation

Polymer Origin Outlook

Delivery Route Outlook

Regional Outlook

Natural

Synthetic

Hybrid

Subcutaneous

Ocular

Oral Cavity

Topical

Other

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

U.S.

Canada

Germany

U.K.

France

Italy

Spain

China

Japan

India

Thailand

South Korea

Brazil

Mexico

Argentina

South Africa

Saudi Arabia

UAE

The Hydrogel-based Drug Delivery System market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.

Request For Report Discounts @https://www.trendsmarketresearch.com/report/discount/13640

The report provides size (in terms of volume and value) of Hydrogel-based Drug Delivery System market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.

This report focuses on the global Hydrogel-based Drug Delivery System market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hydrogel-based Drug Delivery System market development in United States, Europe and China.

It is pertinent to consider that in a volatile global economy, we haven’t just conducted Hydrogel-based Drug Delivery System market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.

[kritikarehani]

Functional Dyspepsia Market Size, Share, Trends, Epidemiology and Market Forecast 2030

Functional dyspepsia is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms.

Functional Dyspepsia Signs and Symptoms 

Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals.

Functional Dyspepsia Epidemiology

According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalence of 10–20%. It affects the gastrointestinal tract. The community prevalence of dyspepsia is typically rated in 20% to 40%, and the disorder estimates 3% to 5% of primary care visits.

Endoscopic research was found to assess the Functional Dyspepsia epidemiology and the recently suggested subgroups of meal-related symptoms and epigastric pain. Of the 1033 subjects, 156 had dyspepsia, and of these, 114 had Functional Dyspepsia. Of the 114 subjects with Functional Dyspepsia, nearly 70% had meal-related symptoms (postprandial fullness and early satiation), and 50% had epigastric discomfort. Around 16% had meal-related symptoms and epigastric Pain; this was fewer than expected by chance alone.

Functional Dyspepsia Treatment Options

Functional dyspepsia that is long-lasting and isn't controlled by lifestyle changes may require treatment. The Functional Dyspepsia treatment depends on your signs and symptoms. Treatment may combine medications with behavior therapy.

Medicines that may help manage the signs and symptoms of functional dyspepsia include over-the-counter gas remedies, medications to reduce acid production, medications that block acid 'pumps,' antibiotics, low-dose antidepressants, prokinetics, medications to relieve nausea (antiemetics).

Functional Dyspepsia Market 

Limited late-stage pipeline activities have been observed in Functional Dyspepsia; besides, most of the trials are either completed, suspended or terminated as per ClinicalTrials.gov. Key players, such as Zeria Pharmaceutical, RaQualia Pharma, ISOThrive, Jiangxi Qingfeng Pharmaceutical, and others, are developing a treatment for functional dyspepsia. 

It is worth mentioning that companies like Johnson & Johnson, Yuhan Corporation, Ironwood Pharmaceuticals, Abide Therapeutics, and several others tried investigating drugs for this indication, but then again faced challenges like recruitment issues [For example; Abide Therapeutics (ABX-1431); Ironwood Pharmaceuticals (IW-9179)]. Yuhan Corporation was also investigating YH12852 in patients with Functional Dyspepsia in phase II clinical trials, however, suspended due to dose re-selection.

In addition, Dong-A Socio Group tried extending its reach across global markets. The company also filed for an IND (Investigational New Drug) application for a phase II clinical trial in the United States for Motilitone. It is a phytomedicine for Functional Dyspepsia and Dong-A ST's third new in-house developed original drug. The company initiated a double-blind, placebo-controlled, randomized, 4-week, Phase II Clinical trial for assessment of efficacy and safety of Motilitone in patients with Functional Dyspepsia. This Phase II study is completed. No recent updates are available.

By accessing the scarcity of late-stage pipeline candidates, and the absence of attentiveness by pharmaceutical companies, it can be assumed that Functional Dyspepsia market size will amplify at a moderate rate during the forecast period (2017-2030). 

[marketreports-world]

Global Drug Device Combination Market - Forecast Till 2027

Drug Device Combination Market Size, Growth and Trends Analysis by Product (catheter, antimicrobial applications, advanced wound care products), Application (coronary angioplasty, tachycardia management), End user (hospitals & clinics) – Global Forecast till 2027

Market Highlights

Following a careful analysis of the latest trends, Market Research Future (MRFR) in its latest report states that the drug device combination market is on track to demonstrate a healthy growth rate of 11.4% during the forecast period (2018-2023).

Growth Drivers and Top Barriers

Drug device combination allows early diagnosis along with shorter treatment duration in most of the surgical procedures. The surge in the demand is also the result of various other benefits including minimal pain, improved safety, cost efficiency, high efficacy, speedy recovery, and decreased hospital stay owing to these devices.

The growing number of regulatory healthcare authorities defining the strict protocols for premarket authorizations is projected to prompt the manufacturers in getting approvals for their products. For instance, the United States (U.S.) FDA had come up with the lean management process mapping approach for developing a more streamlined, cohesive, collaborative and systematic system to analyze the said products. The stringent safety guidelines as well as recommendations by the authorities across the globe are poised to raise the adoption rate of these products in the coming years, stimulating the growth of the overall market.

Adverse side effects linked with therapeutics on account of the drug absorption by certain locations within the body are considered to be the catalysts in the growing need for targeted therapy, which is expected to elevate the demand for drug-device combinations in the process. Case in point is Levodopa, which when consistently administered, could lead to long-term complications including dyskinesia, motor fluctuations, neurotoxic effects and extreme metabolic changes among others. All these factors are set to fuel the clinical need for incorporating alternatives whose basic core is targeted therapy, which is the same with drug-device combination products.

Market Segmentation

The worldwide drug device combination market has been segmented on the basis of product, application, and end user.

In terms of product, the market can be broken down into catheter, advanced wound care products, and others.

Application-wise segments in the market are coronary angioplasty, tachycardia management, non-cardiovascular treatments, peripheral arterial disease (pad), bone treatment, antimicrobial applications, wound care, ophthalmic treatment, and others.

The end users covered in the report include hospitals & clinics, ambulatory centers, and academic & research organization, and others.

Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/6946

Companies Profiled

The leading participants in the worldwide drug device combination are Abbott Laboratories, AlloSource, Biomet Orthopedics, Inc., Wright Medical Group, Inc., Biotronik, Boston Scientific Corporation, St. Jude Medical Inc, 3M Inc., Covidien Ltd, Biometrix Medical, Stryker Corporation, C.R. BARD, Zimmer Holding, Inc., Cook Critical Care, Inc., Smith & Nephew Plc, and others.

Regional Segmentation

The Americas, Europe, Asia Pacific and the Middle East & Africa are the key regions in the global drug device combination market.

The Americas has left other regions in the lurch with the dominant share of the overall market, due to the growing prevalence of cardiovascular diseases coupled with the existence of prominent players based in the region. Moreover, appropriate reimbursement policies, elevated spending on healthcare, and a well-established healthcare industry in the United States (U.S.) and Canada are identified as the crucial drivers for the drug device combination market in the region.

The data experts report that Europe had been at the second position in the global drug device combination market in 2017, with factors like the presence of a highly-developed healthcare infrastructure, surging awareness about the devices and the massive contribution of developed nations in the region backing the market growth. On top of that, a humungous patient pool is powering the regional market further.

Expanding at the fastest growth rate as reported in 2017, Asia Pacific is launching ahead backed by the growing penetration of prominent vendors into the region, booming healthcare sector and rising support of the government for foreign investments. A report furnished by the Indian Brand Equity Foundation in 2017 states that the Indian healthcare industry was predicted to expand at a CAGR of 22.87, with further predictions of it set to reach the valuation of USD 280 billion by the year 2020. These favorable numbers are expected to subsequently work in favor of the drug device combination market in the following years.

Finally, the Middle East and Africa accounts for the smallest share in the worldwide drug device combination market because of the presence of poor countries as well as low per capita income, particularly in the Africa region. The regional market is forecasted to be governed by the Middle East as a result of the growing government funding in a bid to expand the healthcare industry, in addition to the presence of flourishing nations such as the United Arab Emirates, Dubai, Saudi Arabia, among others.

Industry News

May 2019: Medtronic PLC MDT has recently launched the Telescope guide extension catheter that will offer support as well as access to the distal lesions. This product launch reflects the company’s entry marks the company’s entry into the guide extension catheter market and subsequently the drug device combination market.

Table Of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Macroeconomic Indicators

4.5 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

5.2 Value Chain Analysis

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/drug-device-combination-market-6946

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Related Report:

Drug Device Combination Market Analysis - Forecast Report Till 2023

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com

[wiseguyreport1222]

This report presents a comprehensive overview, market shares, and growth opportunities of Injection Mould market by product type, application, key manufacturers and key regions and countries.

GET FREE SAMPLE PDF: https://www.wiseguyreports.com/sample-request/6413468-global-injection-mould-market-growth-2021-2026

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7. Two-plate Injection Mold Three-plate Injection Mould Stack Injection Mold

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8. Automotive Home Appliance Packaging Electrical & Electronics Medical Others

ALSO READ : http://www.marketwatch.com/story/global-internet-of-robotic-things-industry-market-size-share-value-and-competitive-landscape-forecast-year-2021-2026-2021-05-10

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8. Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia

ALSO READ : http://www.marketwatch.com/story/global-pain-management-therapeutics-market-by-type-by-application-by-segmentation-by-region-and-by-country-2021-2021-05-11

Middle East & Africa Egypt South Africa Israel Turkey GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3. TQM Greatoo Himile Aco Mold Tech Mold Nypro Ogihara Adval Tech Roeders Chengfei Integration Technology Tongling Zhongfa Suntech Motor Dies Changhong Technology

ALSO READ : http://www.marketwatch.com/story/global-vision-guided-robots-technology-market-by-type-by-application-by-segmentation-by-region-and-by-country-2020-2021-05-12

Table of Contents

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered

2 Executive Summary 2.1 World Market Overview 2.1.1 Global Injection Mould Consumption 2016-2026 2.1.2 Injection Mould Consumption CAGR by Region 2.2 Injection Mould Segment by Type 2.2.1 Two-plate Injection Mold 2.2.2 Three-plate Injection Mould 2.2.3 Stack Injection Mold 2.3 Injection Mould Sales by Type 2.3.1 Global Injection Mould Sales Market Share by Type (2016-2021) 2.3.2 Global Injection Mould Revenue and Market Share by Type (2016-2021) 2.3.3 Global Injection Mould Sale Price by Type (2016-2021) 2.4 Injection Mould Segment by Application 2.4.1 Automotive 2.4.2 Home Appliance 2.4.3 Packaging 2.4.4 Electrical & Electronics 2.4.5 Medical 2.4.6 Others 2.5 Injection Mould Sales by Application 2.5.1 Global Injection Mould Sale Market Share by Application (2016-2021) 2.5.2 Global Injection Mould Revenue and Market Share by Application (2016-2021) 2.5.3 Global Injection Mould Sale Price by Application (2016-2021)

ALSO READ : http://www.marketwatch.com/story/global-mesoporous-silica-market-size-share-value-and-competitive-landscape-2020-2021-05-13

3 Global Injection Mould by Company 3.1 Global Injection Mould Sales Market Share by Company 3.1.1 Global Injection Mould Sales by Company (2019-2021) 3.1.2 Global Injection Mould Sales Market Share by Company (2019-2021) 3.2 Global Injection Mould Revenue Market Share by Company 3.2.1 Global Injection Mould Revenue by Company (2019-2021) 3.2.2 Global Injection Mould Revenue Market Share by Company (2019-2021) 3.3 Global Injection Mould Sale Price by Company 3.4 Global Manufacturers Injection Mould Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Injection Mould Product Location Distribution 3.4.2 Players Injection Mould Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021) 3.6 New Products and Potential Entrants 3.7 Mergers & Acquisitions, Expansion

4 Injection Mould by Region 4.1 Global Injection Mould by Region 4.1.1 Global Injection Mould Sales by Region 4.1.2 Global Injection Mould Revenue by Region 4.2 Americas Injection Mould Sales Growth 4.3 APAC Injection Mould Sales Growth 4.4 Europe Injection Mould Sales Growth 4.5 Middle East & Africa Injection Mould Sales Growth

ALSO READ : http://www.marketwatch.com/story/global-hvac-motors-industry-market-size-share-value-and-competitive-landscape-forecast-year-2021-2026-2021-05-14

5 Americas 5.1 Americas Injection Mould Sales by Country 5.1.1 Americas Injection Mould Sales by Country (2016-2021) 5.1.2 Americas Injection Mould Revenue by Country (2016-2021) 5.2 Americas Injection Mould Sales by Type 5.3 Americas Injection Mould Sales by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil

….continued

CONTACT DETAILS :

sales@wiseguyreports.com

+44 203 500 2763

+1 62 825 80070

971 0503084105

[your-dietician]

PETVIVO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q/A)

New Post has been published on https://depression-md.com/petvivo-managements-discussion-and-analysis-of-financial-condition-and-results-of-operations-form-10-q-a/

PETVIVO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q/A)

OVERVIEW

PetVivo Holdings, Inc.(the “Company, “we” or “us”) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals.. The Company’s lead product Kush® is scheduled for a focused commercial launch later this year. We have never been profitable.

We were incorporated in Nevada in 2009 under a former name. In 2014, we entered our current business through a reverse merger with PetVivo Inc., a Minnesota corporation founded in 2013. From this merger, PetVivo Inc. became our wholly-owned subsidiary, and concurrently we changed our Nevada corporate name to PetVivo Holdings, Inc.

Until August 10, 2021, our common stock was publicly traded in the over-the-counter (OTC) market and under the symbol “PETV”.

On August 13, 2021, the Company closed a firm commitment underwritten public offering in which it sold an aggregate of 2,500,000 units, to the public at a price of $4.50 per unit, for total net proceeds of approximately $9,800,000, net of commissions and estimated offering costs. Each unit consists of one share of common stock and one warrant to purchase one share of the Company’s common stock at a purchase price of $6.25 per share. The Company’s common stock and warrants are trading on the Nasdaq Capital Market under the symbols “PETV” and “PETVW,” respectively.

CURRENT BUSINESS OPERATIONS

We are an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and therapeutics for pets, based in Minneapolis, Minnesota. We operate in the $31 billion US veterinary care and products market (market size according to the American Pet Products Association). Despite the market size, veterinary clinics and hospitals have very few treatments and/or drugs for use in treating osteoarthritis in pets and other animals. In addition, the role of pets in the family has greatly evolved in recent years as many pet owners consider their pets an important member of the family and are now willing to spend greater amounts of money on their pets to maintain their health and quality of life.

We intend to leverage our investments in the development of human therapeutics to commercialize treatments for pets in a capital and time-efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market earlier than the more-stringently regulated veterinary pharmaceuticals or human therapeutics.

Our lead product, Kush®, is scheduled for focused commercial launch later this year. Kush® is a veterinarian-administered joint injection for the treatment of osteoarthritis and lameness in dogs and horses. The Kush® device is made from natural components that are lubricious and cushioning to perform like cartilage for the treatment of pain and inflammation associated with osteoarthritis.

24

We believe that Kush® is an optimal treatment that safely improves joint function. The Kush® particles are lubricious, cushioning and long-lasting. The spongy, protein-based particles mimic the composition and protective function of cartilage (i.e., providing both a slippery cushion and healing scaffolding) and protect the joint as an artificial cartilage.

Using industry sources, we estimate osteoarthritis afflicts approximately 20 million owned dogs in the United States and the European Union, making canine osteoarthritis an estimated potential $4 billion market opportunity, this does not factor in any contra-lateral usage of the product by veterinarians. See Johnston, Spencer A. “Osteoarthritis. Joint anatomy, physiology, and pathobiology.” The Veterinary clinics of North America (1997):699-723; and http://www.americanpetproducts.org/press_industrytrends.asp.

In addition to being a treatment for osteoarthritis, the joint-cushioning and lubricity effects of Kush® have shown an ability to treat equine lameness that is due to navicular disease (a problem associated with misalignment of joints and bones in the hoof and digits).

Based on a variety of industry sources we estimate that 1 million owned horses in the United Stated and European Union suffer from lameness and/or navicular disease each year, making the equine lameness and navicular disease market an annual opportunity worth $550 million; this does not factor in any contra-lateral usage of the product by veterinarians. See Kane, Albert J., Josie Traub-Dargatz, Willard C. Losinger, and Lindsey P. Garber; “The occurrence and causes of lameness and laminitis in the US horse population” Proc Am Assoc Equine Pract. San Antonio (2000): 277-80; Seitzinger, Ann Hillberg, J. L. Traub-Dargatz, A. J. Kane, C. A. Kopral, P. S. Morley, L. P. Garber, W. C. Losinger, and G. W. Hill. “A comparison of the economic costs of equine lameness, colic, and equine protozoal myeloencephalitis (EPM).” In Proceedings, pp. 1048-1050. 2000; and Kilby, E. R. 10 CHAPTER, The Demographics of the U.S. Equine Population, The State of the Animals IV: 2007.

Osteoarthritis is a condition with degenerating cartilage, creating joint stiffness from mechanical stress resulting in inflammation and pain. The lameness caused by osteoarthritis worsens with time from the ongoing loss of protective cushion and lubricity. There are currently very few treatments for osteoarthritis; some of which are palliative pain therapy and joint replacement. Non-steroidal, anti-inflammatory drugs (NSAIDs) are used to alleviate the pain and inflammation, but long-term use has been shown to cause gastric problems. NSAIDs do not treat the cartilage degeneration issue to halt or slow the progression of the osteoarthritis condition.

We believe that our treatment of osteoarthritis in canines using Kush® is far superior to the current methodology of using NSAIDs. NSAIDs have many side effects, especially in canines, whereas the company’s treatment using Kush®, to our knowledge, has not elicited any adverse side effects in dogs. Remarkably, Kush®-treated dogs have shown an increase in activity even after they no longer are receiving pain medication.

No special training is required for the administration of the Kush device. The treatment is injected into synovial joint space using standard intra-articular injection technique and multiple joints can be treated simultaneously. Kush® immediately treats effects of osteoarthritis with no special post-treatment requirements.

Historically, drug sales represent up to 30% of revenues at a typical veterinary practice (Veterinary Practice News). Revenues and margins at veterinary practices are being eroded because online, big-box and traditional pharmacies recently started filling veterinary prescriptions. Veterinary practices are looking for ways to replace the lost prescription revenues. The Kush® device is veterinarian-administered and should expand practice revenues and margins. We believe that the increased revenues and margins provided by Kush® will accelerate its adoption rate and propel it forward as the standard of care for canine and equine lameness related to or due to synovial joint issues. If we are capitalized in a way the Company feels acceptable to move forward with commercial manufacturing of Kush®, our challenge will be whether we can consistently operate effectively to manufacture our products and to market and sell them in quantities and prices sufficient to obtain a satisfactory and sustaining profit. We have not done this to date and our challenge is to do so going forward.

We anticipate growing our product pipeline through the acquisition or in-licensing of additional proprietary products from human medical device companies specifically for use in pets. In addition to commercializing our own products in strategic market sectors and in view of the company’s vast proprietary product pipeline, the Company is seeking to continue to develop strategic out-licensing partnerships to provide secondary revenues.

25

We plan to commercialize our products in the United States through distribution relationships supported by regional and national distributors and complemented by the use of digital marketing to educate and inform pet owners; and in Europe and the rest of the world through commercial partners. In September 2019, the Company entered into an agreement with a service provider to film a 12-part, monthly series of interviews with our CEO, John Lai, Company key opinion leaders, and other media content to be aired on Bloomberg Television Network alongside 96 commercials; we anticipate this program to begin in the second half of 2021.

Most veterinarians in the United States buy a majority of their equipment and supplies from one of four veterinary-product distributors. Combined, these four distributors deliver more than 85%, by revenue, of the products sold to companion animal veterinarians in the U.S. We plan to have our product distribution leverage the existing supply chain and veterinary clinic and clinician relationships already established by these large distributors. We plan to support this distribution channel with regional sales representatives. Our representatives will support our distributors alongside the veterinary clinics and hospitals. We will also target pet owners with product education and treatment awareness campaigns utilizing a variety of digital marketing tools. The unique nature and the anticipated benefits provided by our products are expected to generate significant consumer response.

Our biomaterials have been through a human clinical trial and have been classified as a medical device for use as a dermal filler. The FDA does not require submission of a 510(k) or formal pre-market approval for medical devices used in veterinary medicine.

RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and related notes that appear elsewhere in this prospectus. In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to those differences include those discussed below and elsewhere in this prospectus, particularly in “RISK FACTORS.” We caution the reader not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date of this prospectus.

We are a smaller reporting company and have not generated any material revenues to date and have incurred substantial losses in connection with our limited operations. We need substantial capital to pursue our current plans to bring our first products to market. The first of such products is a proprietary gel-like protein-based biomedical material for injection into the afflicted body parts of animals suffering from osteoarthritis or other impairments to be marketed under the trade name Kush®. It will provide to veterinarians an innovative treatment for dogs and horses suffering from osteoarthritis.

RESULTS OF OPERATION For the Three Months Ended June 30, 2021 June 30, 2020 Revenues $ 4,145 $ 2,006 Total Cost of Sales 5,051 - Total Operating Expenses 517,613 444,074 Total Other Income (Expense) 27,890 (371,940 ) Net Loss $ (490,629 )$ (814,008 )

Net loss per share – basic and diluted $ (0.07 ) $ (0.16 )

* In October 2020, the Company approved a 1-for-4 reverse split of our outstanding shares of common stock that was made effective December 29, 2020. All share and per share data has been retroactively adjusted for this reverse split for all period presented.

26

For The Three Months Ended June 30, 2021 Compared to The Three Months Ended June 30, 2020

Total Revenues. Revenue was $4,145 and $2,016 for three months ended June 30, 2021 and 2020, respectively, and consisted of Kush® sales to veterinary clinics.

Total Cost of Sales. Cost of sales was $5,051 and $-0– for the three months ended June 30, 2021 and 2020, respectively.

Operating Expenses. Operating expenses were $517,613 and $444,074 for the three months ended June 30, 2021 and 2020, respectively. Operating expenses consisted of general and administrative, sales and marketing, and research and development expenses.

General and administrative (“G&A”) expenses were $397,392 and $330,945 for the three months ended June 30, 2021 and 2020, respectively. General and administrative expenses include corporate overhead, financial and administrative contracted services, consulting fees and stock compensation costs.

Sales and marketing expenses were $46,682 and $49,731 for the three months ended June 30, 2021 and 2020, respectively.

Research and development (“R&D”) expenses were $136,97 and $ -0– for the three months ended June 30, 2021 and 2020, respectively. The increase was related to efforts to support the launch of Kush®.

Operating Loss. As a result of the foregoing, our operating loss was $518,519 and $442,068 for the three months ended June 30, 2021 and 2020.

Other Income (Expense). Other income was $27,890 for the three months ended June 30, 2021 as compared to other expense of $371,940 for the three months ended June 30, 2020. Other income in 2021 consisted of the foregiveness of PPP Loan and accrued interest of $31,680 partially offset by interest expense of $3,790. Other expense in 2020 consisted primarily of derivative expense related to debt financing of $342,200 and interest expense of $30,222.

Net Loss. Our net loss for the three months ended June 30, 2021 as 490,629 or ($0.07) as compared to a net loss of $814,008 or ($0.16) per share for the three months ended June 30, 2020. Net loss decreased primarily due to the derivative expense recognized on the debt financing in 2020. The weighted average number of shares outstanding was 6,946,353 compared to 5,161,101 for the three months ended June 30, 2021 and 2020, respectively.

LIQUIDITY AND CAPITAL RESOURCES

Our financial position and future prospects depend significantly on our access to financing to fund our operations during our development stage. Much of our current cost structure is based on costs related to personnel and facilities, and not subject to material variability. In order to fund our operations and working capital needs, we historically have utilized loans from accredited investors and others, equity sales of common stock to accredited investors and others having pre-existing relationships with us, and substantial issuances of stock-based compensation to satisfy outstanding debt and pay for development, management, financial, professional and other services.

As of June 30, 2021, our current assets were $245,634 including $143,084 in cash and $102,550 in prepaid expenses. In comparison, our current liabilities as of that date were $1,340,555 consisting of $1,149,040 of accounts payable and accrued expenses, $50,898 of accrued expenses – related party, $7,436 in PPP loan, $20,300 in notes payable and accrued interest – directors, $48,267 in notes payable and accrued interest – related party, $37,860 in a note payable and $26,754 in operating lease liability – short term. Our working capital deficiency as of June 30, 2021 was $1,094,921.

27

We will need to raise substantial additional capital through private or public offerings of our equity or debt securities, or a combination thereof, and we may have to use a material portion of any capital raised to repay past due debt obligations. To the extent any capital raised is insufficient to both satisfy operational working capital needs and meet any required debt payments, we will most likely need to either extend, refinance or convert to equity our outstanding indebtedness.

We currently have little cash to support our operations and projected commercial growth. Accordingly, we will require substantial additional financing to fund our operational working capital for at least the next 12 months. Financing may be sought by us from several sources such as private or public sales of our equity or convertible debt securities, and/or loans from affiliates, banks or other financial institutions. We have filed Forms S-1 and S-1/A with the Securities and Exchange Commission on October 13, 2020, December 31, 2020, March 29, 2021 and July 13, 2021, respectively, to raise capital through a public offering of our common stock. In the event we cannot obtain any such financing when needed on terms acceptable to us, if at all, our business would suffer substantially.

Liquidity represents the ability of a company to generate sufficient cash to provide for its immediate cash needs, which our continued losses have made it difficult for us to accomplish. Over the past several years we have continued to incur substantial losses without any source of material revenues or liquid assets, which has caused a serious and harmful effect to our liquidity and a substantial strain on our ongoing business operations.

We have not generated any operating cash flows since we are a development stage company which has not yet realized any significant commercial revenues.

Net Cash Used in Operating Activities – We used $255,861 of net cash in operating activities for the three months ended June 30, 2021. This cash used in operating activities was primarily attributable to our net loss of $490,629, forgiveness of PPP loan and accrued interest of $31,680 and an increase in deferred issue costs of $25,190 partially offset by an increase in accounts payable and accrued expenses of $182,949 and stock compensation expense of $55,674.

Net Cash Used in Investing Activities – We used $6,063 of net cash in investing activities for the three months ended June 30, 2021, consisting of costs capitalized to patents and trademarks.

Net Cash Provided by Financing Activities – During the three months ended June 30, 2021, we were provided with net cash of $381,430 from financing activities consisting of $383,098 in stock and warrants sale proceeds, which were partially offset by $1,668 in repayments of note payable.

Inventory

Inventories are stated at cost, subject to the lower of cost or net realizable value. Cost includes materials, labor, and manufacturing overhead related to the purchase and production of inventories. Net realizable value is the estimated selling price less estimated costs of completion, disposal, and transportation. We regularly review inventory quantities on hand through an inventory count.

At June 30, 2021, the Company’s inventory has a carrying value of $0 and is broken down into $324,123 of finished goods inventory, $6,273 in raw material inventory, and $1,072 in packaging inventory offset by a reserve of $41,468.

At March 31, 2021, the Company’s inventory has a carrying value of $0 and is broken down into $36,973 of finished goods inventory, $8,773 in raw material inventory, and $1,322 in packaging inventory offset by a reserve of $47,068.

28 MATERIAL COMMITMENTS Accrued Salary

We are indebted to certain related parties with respect to unreimbursed expenses and accrued salaries of $50,898 at June 30, 2021. This amount is included in accrued expenses – related party.

Notes Payable

As of June 30, 2021, we are obligated on notes and accrued interest of $113,863 consisting of notes to third parties of $45,296 and to related parties of $68,567.

OFF-BALANCE SHEET ARRANGEMENTS

As of June 30, 2021, and as of the date of this Annual Report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

GOING CONCERN

The independent auditors’ report accompanying our March 31, 2021 Form 10-K and financial statements contains an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern. The financial statements have been prepared assuming that we will continue as a going concern, which contemplates that we will realize our assets and satisfy our liabilities and commitments in the ordinary course of business. We have suffered recurring losses from operations and have a working capital deficit. These factors raise substantial doubt about our ability to continue as a going concern.

We are presently seeking to address these going concern doubts through a number of actions including efforts to (a) raise additional capital and (ii) commencing a focused commercial launch of Kush® later this year. On August 13, 2021, we completed a firm commitment underwritten public offering in which we sold 2.5 million units at a purchase price of $4.50 per share and raised net proceeds of $9.8 million, after deducting underwriter’s commissions and expenses. We can provide no assurance that any of these efforts will be successful or, that even if successful, that they will alleviate doubts about our ability to continue as a going concern for more than the next twelve months.

CRITICAL ACCOUNTING POLICIES

We prepare our consolidated financial statements in accordance with generally accepted accounting standards in the United States of America. Our significant accounting policies are described in Note 1 to our consolidated financial statements attached hereto. We believe the following critical accounting policies involve the most significant judgments and estimates used in the preparation of the consolidated financial statements.

RECENTLY ISSUED ACCOUNTING STANDARDS

The following describes the recently issued accounting standards used in reporting our financial condition and results of operations. In some cases, accounting standards allow more than one alternative accounting method for reporting. In those cases, our reported results of operations would be different should we employ an alternative accounting method.

The FASB issued ASC 606 as guidance on the recognition of revenue from contracts with customers in May 2014 with amendments in 2015 and 2016. Revenue recognition will depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented, or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The company adopted the guidance on April 1, 2018 and applied the cumulative catch-up transition method. There was no transition adjustment upon adoption of the new standard.

29

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this ASU supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use (“ROU”) asset representing its right to use the underlying asset for the lease term. The Company adopted Topic 842 on April 1, 2019 and resulted in a right of use asset and liability of $154,917.

All newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

© Edgar Online, source Glimpses

Source link

[vivekbajaj-grs]

Global Neurostimulation Devices Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

Neurostimulation is a therapeutic activation of part of the nervous system using microelectrodes. The electrodes are used to interface with excitable tissue in order to either restore sensation, such as a cochlear implant for hearing, or control anorgan, such as a heart pacemaker.

Neurostimulation technology improves the life quality of those who are severely paralyzed or suffering from profound losses to various sense organs. It serves as the key part of neural prosthetics for hearing aids, artificial vision, artificial limbs, and brain-machine interfaces. In the case of neural stimulation, mostly an electrical stimulation is utilized and charge-balanced biphasic constant current waveforms of capacitive coupled charge injection approaches are adopted. Alternatively, the transcranial magnetic stimulation has been proposed as a non-invasive method in which a magnetic field causes neurostimulation.

Neurostimulation devices are implantable devices that help in the therapeutic activation of the nervous systems. These devices deliver electrical stimulation to the brain and nervous systems for the treatment of various types of neurological disorders such as pain, epilepsy, Parkinson's disease, depression, obsessive-compulsive disorder, dystonia, and tremors. These devices target specific areas of the brain or spinal cord by blocking the pain messages before they reach the brain.

Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-neurostimulation-devices-2021-2027-922

Global Neurostimulation Devices key players include Medtronic, Boston Scientific, St. Jude Medical (Abbott), etc. Global top three manufacturers hold a share over 75%.

North America is the largest market, with a share over 40%, followed by China, and Europe, both have a share about 40 percent.

In terms of product, Spinal Cord Stimulation (SCS) is the largest segment, with a share over 55%. And in terms of application, the largest application is Pain Management, followed by Parkinson?s Disease, Epilepsy, Urinary and Fecal Incontinence, etc.

Market Analysis and Insights: Global Neurostimulation Devices Market

In 2020, the global Neurostimulation Devices market size was US$ 5981 million and it is expected to reach US$ 12620 million by the end of 2027, with a CAGR of 11.3% during 2021-2027.

Global Neurostimulation Devices Scope and Market Size

Neurostimulation Devices market is segmented by region, by country, company, type, application and by sales channels. Players, stakeholders, and other participants in the global Neurostimulation Devices market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region, by country, company, type, application and by sales channels for the period 2016-2027.

Segment by Type, the Neurostimulation Devices market is segmented into

Spinal Cord Stimulation (SCS)

Gastric Electric Stimulation (GES)

Deep Brain Stimulation (DBS)

Sacral Nerve Stimulation (SNS)

Vagus Nerve Stimulation (VNS)

Other

Segment by Application, the Neurostimulation Devices market is segmented into

Pain Management

Parkinson?s Disease

Urinary and Fecal Incontinence

Epilepsy

Gastroparesis

Other

Regional and Country-level Analysis:

North America

United States

Canada

Asia-Pacific

China

Japan

South Korea

India

Southeast Asia

Australia

Rest of Asia-Pacific

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Rest of Europe

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Competitive Landscape and Neurostimulation Devices Market Share Analysis

Neurostimulation Devices market competitive landscape provides details and data information by companies. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2016-2021. Details included are company description, major business, Neurostimulation Devices product introduction, recent developments, Neurostimulation Devices sales by region, type, application and by sales channel.

The major companies include:

Medtronic

Boston Scientific

Abbott

LivaNova

Nevro

NeuroPace

Beijing Pins

Synapse Biomedical

Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-neurostimulation-devices-2021-2027-922

Table of content

1 Study Coverage 1.1 Neurostimulation Devices Product Introduction 1.2 Market by Type 1.2.1 Global Neurostimulation Devices Market Size Growth Rate by Type 1.2.2 Spinal Cord Stimulation (SCS) 1.2.3 Gastric Electric Stimulation (GES) 1.2.4 Deep Brain Stimulation (DBS) 1.2.5 Sacral Nerve Stimulation (SNS) 1.2.6 Vagus Nerve Stimulation (VNS) 1.2.7 Other 1.3 Market by Application 1.3.1 Global Neurostimulation Devices Market Size Growth Rate by Application 1.3.2 Pain Management 1.3.3 Parkinson?s Disease 1.3.4 Urinary and Fecal Incontinence 1.3.5 Epilepsy 1.3.6 Gastroparesis 1.3.7 Other 1.4 Study Objectives 1.5 Years Considered 2 Executive Summary 2.1 Global Neurostimulation Devices Market Size Estimates and Forecasts 2.1.1 Global Neurostimulation Devices Revenue 2016-2027 2.1.2 Global Neurostimulation Devices Sales 2016-2027 2.2 Neurostimulation Devices Market Size by Region: 2021 Versus 2027 2.3 Neurostimulation Devices Sales by Region (2016-2027) 2.3.1 Global Neurostimulation Devices Sales by Region: 2016-2021 2.3.2 Global Neurostimulation Devices Sales Forecast by Region (2022-2027) 2.3.3 Global Neurostimulation Devices Sales Market Share by Region (2016-2027) 2.4 Neurostimulation Devices Market Estimates and Projections by Region (2022-2027) 2.4.1 Globa

CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 / +91 8087042414 Email: help@grandresearchstore.com Follow Us On linkedin :- https://www.linkedin.com/company/grand-research-store/